Pfizer to acquire Encysive in $195 million deal

Share this article:
Pfizer regroups businesses under global umbrellas
Pfizer regroups businesses under global umbrellas

Pfizer has entered into a deal to acquire publicly-held Houston biotech firm Encysive Pharmaceuticals for $195 million.

The transaction is expected to close in the second quarter of 2008.

Under terms of the deal, Pfizer will acquire rights to Encysive's pulmonary arterial hypertension (PAH) treatment Thelin (sitaxsentan sodium), which is already available in the UK and Europe Union, Australia and Canada. In the US, Thelin has been the subject of three approvable letters from the FDA. Pfizer plans to conduct a pivotal Phase III trial to support registration in the US.

“The acquisition of Encysive will add growing, near-term revenue from the European market and increase our already strong presence in the cardio-respiratory arena with a product that complements Revatio, a PAH treatment that was discovered and developed by Pfizer researchers," said Ian Read, president of Pfizer's worldwide pharmaceutical operations. "We look forward to applying Pfizer's significant resources to the launch of Thelin in additional countries."

PAH is a progressive, incurable disease that is estimated to affect 100,000 to 200,000 people in North America and Europe, including about 55,000 persons in the US.

 

Share this article:

Email Newsletters

More in News

BI rethinks hepatitis business, posts 2013 results

BI rethinks hepatitis business, posts 2013 results

Boehringer Ingelheim says it is no longer pursuing an interferon-free combination of faldaprevir and deleobuvir.

Roche wraps quarter with two fewer pipeline medications

Roche wraps quarter with two fewer pipeline medications

Roche also announced first-quarter sales shrank 1%.

2013 favored specialists, specialty Rx

2013 favored specialists, specialty Rx

The latest IMS Institute for Healthcare Informatics assessment of 2013's prescription drug use shows that 2.3% of prescriptions account for 30% of a patient's out-of-pocket prescription costs.